ClinicalTrials.gov
ClinicalTrials.gov Menu

Combining Sunitinib, Temozolomide and Radiation to Treat Patients Diagnosed With Glioblastoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02928575
Recruitment Status : Unknown
Verified October 2016 by Bassam Abdulkarim, McGill University Health Center.
Recruitment status was:  Recruiting
First Posted : October 10, 2016
Last Update Posted : October 10, 2016
Sponsor:
Collaborators:
Pfizer
Canadian Cancer Society Research Institute (CCSRI)
Information provided by (Responsible Party):
Bassam Abdulkarim, McGill University Health Center

Brief Summary:
The purpose of this study is to determine whether a combination of Sunitinib, Temozolomide and Radiation Therapy would be effective in the treatment of newly diagnosed Glioblastoma patients harboring tumors with unmethylated MGMT promoter.

Condition or disease Intervention/treatment Phase
Glioblastoma Multiforme Drug: Sunitinib Drug: Temozolomide Radiation: Radiation Therapy Phase 2

Detailed Description:

Glioblastoma multiforme (GBM), the most common primary brain tumor in adults is known for its highly invasive and angiogenic profile. Despite advances in different modalities of GBM treatment, the overall prognosis of GBM remains dismal. The current standard of care is Radiation Therapy (RT) at a dose of 60 Gy (30 fractions) for 6 weeks with concurrent Temozolomide (TMZ; 75 mg/m2 daily for 6 weeks) followed by adjuvant TMZ (150/200mg/m2 daily, for 5 of 28 days x 6 months). The DNA repair protein O6-methylguanine methyltransferase (MGMT) removes alkyl adducts at the O6 position of guanine and therefore counteracts the cytotoxic effects of alkylating agents such as TMZ. Thus, GBM patients harboring tumors with unmethylated MGMT promoter and increased MGMT protein expression do not derive benefit from TMZ treatment.

Sunitinib (Sutent, SU11248) is an oral multitargeted receptor tyrosine kinase (RTK) inhibitor with anti-angiogenic activities. Sunitinib has been approved by the FDA for the treatment of patients with gastrointestinal stromal tumors after disease progression on or intolerance to imatinib, for the treatment of patients with advanced renal cell carcinoma and for the treatment of patients with unresectable, locally advanced, or metastatic well-differentiated pancreatic neuroendocrine tumors (pNET). Previous pre-clinical data showed the efficacy of sunitinib in GBM. The investigators preclinical data highlighted the differential effect of sunitinib in GBM MGMT-positive tumors with a greater response to sunitinib in combination with RT and TMZ compared to MGMT-negative tumors.

In this phase II trial, Investigator will test the efficacy and the safety of combining Sunitinib with RT and TMZ in newly diagnosed GBM patients displaying tumors with unmethylated MGMT promoter. Based on the investigators preclinical findings, patients with MGMT (+) tumors (do not derive benefit from TMZ treatment) are more likely to respond to sunitinib-based therapy. MGMT promoter methylation will be therefore used as a biomarker for selection of newly diagnosed GBM patients enrolled in this study.


Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 45 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II Trial of Concurrent Sunitinib, Temozolomide and Radiation Therapy Followed by Adjuvant Temozolomide for Newly Diagnosed Glioblastoma Patients With an Unmethylated MGMT Gene Promoter
Study Start Date : August 2012
Estimated Primary Completion Date : December 2016
Estimated Study Completion Date : June 2017


Arm Intervention/treatment
Experimental: Sunitinib, Temozolomide and Radiation Therapy
Before concurrent treatment, patients will receive sunitinib orally at a dose of 12.5 mg once daily for one week prior to radiation. Patients will then receive a concomitant treatment of sunitinib at a dose of 12.5 mg once daily along with temozolomide (75 mg/m2 daily) along with radiotherapy (60 Gy in 30 fractions) over a period of 6 weeks. This concurrent treatment of sunitinib, temozolomide and radiotherapy is followed by a 1 month break after which the adjuvant temozolomide treatment is administered at a dose of 150/200mg/m2 daily, for 5 of 28 days over a period of 6 months.
Drug: Sunitinib
Before concurrent treatment, patients will receive sunitinib orally at a dose of 12.5 mg once daily for one week prior to radiation. Patients will then receive a concomitant treatment of sunitinib at a dose of 12.5 mg once daily along with temozolomide (75 mg/m2 daily) along with radiotherapy (60 Gy in 30 fractions) over a period of 6 weeks.
Other Name: Sutent (SU11248)

Drug: Temozolomide
Temozolomide (75 mg/m2 daily) will be administered along with sunitinib (12.5 mg once daily) and radiotherapy (60 Gy in 30 fractions) over a period of 6 weeks. This concurrent treatment of sunitinib, temozolomide and radiotherapy is followed by a 1 month break after which the adjuvant temozolomide treatment is administered at a dose of 150/200mg/m2 daily, for 5 of 28 days over a period of 6 months.

Radiation: Radiation Therapy
Patients will receive a concomitant treatment of radiotherapy (60 Gy in 30 fractions), sunitinib (12.5 mg once daily) and temozolomide (75 mg/m2 daily) over a period of 6 weeks.




Primary Outcome Measures :
  1. Tumor Response Rate [ Time Frame: 24 weeks ]
    The primary endpoint of this study is tumor response rate and will be assessed using the Response Assessment in Neuro-Oncology criteria (RANO). Tumor response rate will be compared to standard of care in newly diagnosed Glioblastoma Multiforme.


Secondary Outcome Measures :
  1. Overall Survival [ Time Frame: at 6 month post treatment ]
  2. Progression free survival [ Time Frame: 6 months post treatment ]
  3. Biomarkers (Cytokines) response [ Time Frame: at 6 months post treatment ]
    PDGF, VEGF, sVEGF-R1 / R-2, basic fibroblast growth factor (bFGF), EGF, placental growth factor (PIGF), stromal cell-derived factor-1α (SDF-1), interleukin (IL) -1β, IL-6, IL-8, transforming growth factor α (TGF- α), angiopoietin 1 (Ang1), angiopoietin 2 (Ang2), and soluble Tek/Tie2 receptor (sTie2)

  4. Adverse Events [ Time Frame: Assessment of toxicity will continue until week 13 post-sunitinib ]
    Investigator will assess long-term tolerance/toxicity of Sunitinib-based therapy. Toxicity will be scored using NCI Clinical Trials Criteria for Adverse Events (CTCAE) Version 3.0 (http://ctep.info.nih.gov/).

  5. level of functioning [ Time Frame: at 6 months post treatment ]
    Will be measured using Eastern Cooperative Oncology Group (ECOG performance status) 0-5

  6. Increase use of corticosteroids [ Time Frame: at 6 months post treatment ]
    Increase in corticosteroid dosage by 50%; in the absence of other clinical explanations (such as pseudoprogression) may indicate tumour progression. Calling this evolution clinical tumour progression is at the investigator's discretion.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Histologically documented newly diagnosed GBM patients
  • Unmethylated MGMT promoter as determined by Methylation specific-polymerase chain reaction (MGMT(+) tumor)
  • Age between 18 to 70
  • Karnofsky performance status ≥70
  • History and physical examination including neurologic examination within 4 weeks prior to registration
  • Systolic blood pressure ≤ 160 mmHg or diastolic pressure ≤ 100mm Hg
  • Required blood work within 14 days prior to registration
  • Eligible for standard concurrent chemoradiation with TMZ
  • Patients must have normal organ and marrow functions as defined below:

    • Absolute neutrophil count ≥ 1.5x 109/L
    • Platelets ≥100x 109/L
    • Hemoglobin ≥80g/L
    • International Normalized Ratio ≤1.3
    • Creatinine ≤1.5x [upper limit of normal] Or creatinine clearance ≥60 mL/min/1.73m2
  • Normal baseline thyroid function as measured by a thyrotropic-stimulating hormone within institutional normal limits
  • Adequate liver function: Alanine transaminase or Aspartate transaminase < 2 x upper limit of normal and bilirubin 1.6 mg/dL. No active bleeding or pathologic condition that carries high risk of bleeding (e.g. tumor involving major vessels or known varices)
  • Patients who have undergone resection must meet the following conditions:

    • Patients must have recovered from the effects of surgery and a minimum of 14 to 28 days must have elapsed from the day of surgery to day of registration. Day of registration is considered the first day of Sunitinib.
    • For stereotactic biopsy, a minimum of 14 days must have elapsed prior to registration
  • No prior RT to the brain, chemotherapy, or anti-angiogenic therapy
  • Estimated life expectancy of at least 6 months
  • Premenopausal women must have a negative human chorionic gonadotropin within 14 days prior to registration
  • The effects of Sunitinib on the developing human fetus is unknown. Women of childbearing potential and male participants must practice adequate contraception. Should a woman become pregnant or suspect she is pregnant during the study, she should inform her treating physician immediately.
  • Ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria:

  • Histologically documented newly diagnosed GBM patients with methylated MGMT promoter
  • Serious medical conditions that might be aggravated by treatment, including but not limited to: myocardial infarction within 6 months, congestive heart failure, unstable angina, active cardiomyopathy, unstable ventricular arrhythmia, uncontrolled hypertension, uncontrolled psychotic disorders, serious infections, active peptic ulcer disease, active liver disease or cerebrovascular disease with previous stroke
  • Patients with a history of coagulopathy
  • Evidence of intratumoural or peritumoural hemorrhage deemed significant by the treating physician
  • ≥ 1+ proteinuria on two successive urine dipstick assessments
  • thrombolytic therapy within 4 weeks
  • Patient with prolonged of corrected QT interval of more than 450 msec in screening EKG will be excluded
  • Women who are pregnant or nursing
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to Sunitinib
  • Previous treatment with Sunitinib or other inhibitors of the vascular endothelial growth factor signalling axis
  • Bleeding disorders
  • Concurrent use of anticoagulant or antiplatelet drugs
  • Patients with any condition that impairs their ability to swallow Sunitinib (e.g. gastrointestinal tract disease resulting in an inability to take oral medication or a requirement for IV alimentation, prior surgical procedures affecting absorption, or active peptic ulcer disease).
  • HIV-positive patients on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with Sunitinib. In addition, these patients are at increased risk of lethal infections when treated with bone marrow-suppressive therapy
  • Individuals with MRI non-compatible metal in the body, or unable to undergo MRI procedures.
  • Allergy to gadolinium
  • Patients with severe liver impairment will not be enrolled in this study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02928575


Contacts
Contact: Bassam Abdulkarim, MD PhD FRCPC 514-934-1934 ext 43915 bassam.abdulkarim@mcgill.ca

Locations
Canada, Alberta
Tom Baker Cancer Center and University of Calgary Recruiting
Calgary, Alberta, Canada, T2N 4N2
Contact: Jacob Easaw, MD PhD FRCPC    403-521-3446    Jay.Easaw@albertahealthservices.ca   
Canada, Quebec
McGill University Health Centre Recruiting
Montreal, Quebec, Canada, H4A 3J1
Contact: Bassam Abdulkarim, MD PhD FRCPC    514-934-1934 ext 43915    bassam.abdulkarim@mcgill.ca   
Sponsors and Collaborators
Bassam Abdulkarim
Pfizer
Canadian Cancer Society Research Institute (CCSRI)

Publications:

Responsible Party: Bassam Abdulkarim, PhD, MD, McGill University Health Center
ClinicalTrials.gov Identifier: NCT02928575     History of Changes
Other Study ID Numbers: McG 1132
First Posted: October 10, 2016    Key Record Dates
Last Update Posted: October 10, 2016
Last Verified: October 2016

Keywords provided by Bassam Abdulkarim, McGill University Health Center:
Glioblastoma
Sunitinib
Temozolomide
Radiation Therapy,
MGMT
Biomarkers

Additional relevant MeSH terms:
Glioblastoma
Astrocytoma
Glioma
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Temozolomide
Dacarbazine
Sunitinib
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors